Mainz Biomed NV (MYNZ)
(Delayed Data from NSDQ)
$0.36 USD
+0.01 (3.40%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $0.36 0.00 (0.28%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.36 USD
+0.01 (3.40%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $0.36 0.00 (0.28%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Absci Corporation (ABSI) delivered earnings and revenue surprises of -15.79% and 37.93%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 44.70% and 0.49%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
MeiraGTx (MGTX) delivered earnings and revenue surprises of -145.16% and 98.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Adma Biologics (ADMA) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of 62.50% and 23.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 19.30% and 45.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 9.68% and 8.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 8% and 10.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Precigen (PGEN) delivered earnings and revenue surprises of -11.11% and 30.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 66.67% and 1.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of -78.57% and 4.05%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
What Makes Mainz Biomed NV (MYNZ) a New Buy Stock
by Zacks Equity Research
Mainz Biomed NV (MYNZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).